Text Size
3937 studies found for:    Lymphoma

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Unknown † Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-Grade Lymphoma in Adults
Conditions: Burkitt's Lymphoma;   Burkitt's Leukemia;   Mediastinal Neoplasms;   Lymphoblastic Lymphoma;   Large Cell Anaplastic Lymphoma
Interventions: Drug: Adriamycin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone/Prednisolone;   Drug: VP16;   Drug: Ifosfamide;   Drug: Methotrexate;   Drug: G-CSF;   Drug: Rituximab;   Drug: Vincristine/Vindesine;   Procedure: Irradiation (in specific conditions)
2 Unknown † Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma (Not Otherwise Specified);   Angioimmunoblastic T-cell Lymphoma;   Extranodal NK/T-cell Lymphoma Nasal Type;   Enteropathy- Type T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative);   Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
Intervention: Drug: panobinostat and bortezomib
3 Active, not recruiting First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma
Interventions: Drug: Rituximab, Cyclophosphamide, Vincristine, Prednisone;   Drug: Rituximab, Cyclophosphamid, Doxorubicin, Vincristine, Prednisone
4 Unknown † Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell, and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
Conditions: Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Diffuse Large Cell Lymphoma;   Mantle Cell Lymphoma;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Biological: ISF35
5 Recruiting Tandem Auto-Allo Transplant for Lymphoma
Conditions: Diffuse, Large B-Cell, Lymphoma;   Lymphoma, Low-Grade;   T-Cell Lymphoma;   Mantle-Cell Lymphoma;   Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
Interventions: Drug: Busulfan;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Phenytoin;   Drug: Ursodiol;   Other: Infusion of autologous peripheral blood stem cells;   Drug: Neupogen;   Drug: Fludarabine;   Other: Peripheral blood stem cell transplant;   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Methotrexate
6 Recruiting Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
Conditions: Lymphoma;   Mantle Cell Lymphoma;   Indolent Lymphoma;   SLL
Interventions: Drug: rituximab;   Drug: bortezomib;   Drug: cladribine
7 Recruiting Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
Conditions: Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: pegfilgrastim;   Biological: rituximab;   Other: flow cytometry;   Procedure: biopsy;   Other: immunohistochemistry staining method;   Genetic: western blotting
8 Recruiting Safety and Efficacy Study of CAL-101 in Patients With Previously Treated Low-grade Lymphoma
Conditions: Indolent Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma
Intervention: Drug: CAL-101
9 Active, not recruiting Imexon for Relapsed Follicular and Aggressive Lymphomas
Conditions: Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma;   Lymphoplasmacytic Lymphoma;   Diffuse Large B Cell Lymphoma;   Mantle Cell Lymphoma;   Burkitt's Lymphoma
Intervention: Drug: Imexon
10 Suspended Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Conditions: Hodgkin's Lymphoma;   Low Grade Lymphoma;   Lymphoma;   Mantle Cell Lymphoma;   Non-Hodgkin's Lymphoma;   Diffuse Large Cell Lymphoma
Interventions: Drug: AMG 655;   Other: Vorinostat;   Other: Bortezomib
11 Withdrawn Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
Conditions: AIDS-related Lymphoma;   Adult Non-Hodgkin's Lymphoma;   Anaplastic Large Cell Lymphoma
Interventions: Drug: cisplatin;   Drug: cytarabine;   Drug: etoposide;   Drug: methylprednisolone;   Drug: rituximab;   Drug: yttrium Y 90 ibritumomab tiuxetan;   Procedure: antibody therapy;   Procedure: biological therapy;   Procedure: chemotherapy;   Procedure: monoclonal antibody therapy;   Procedure: radiation therapy;   Procedure: radioimmunotherapy;   Procedure: radioisotope therapy
12 Recruiting A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Eltrombopag and Vorinostat
13 Unknown † Lenalidomide and R-CHOP in B-cell Lymphoma
Conditions: Lymphoma, Large B-Cell, Diffuse;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone B-Cell Lymphoma
Intervention: Drug: Lenalidomide and R-CHOP
14 Terminated
Has Results 		Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
Conditions: Burkitt Lymphoma;   Non-Hodgkins Lymphoma;   Atypical Burkitt Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Leucovorin;   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Mesna
15 Terminated Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: MTD of Velcade, Nipent and Rituxan established in Part 1
16 Recruiting Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   AIDS-related Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   HIV Infection;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: vorinostat;   Drug: prednisone;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: etoposide;   Other: laboratory biomarker analysis
17 Recruiting Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Conditions: Diffuse Large B-cell Lymphoma;   de Novo DLBCL;   DLBCL Transformed From Indolent Lymphoma;   Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab;   Drug: Gemcitabine + Rituximab
18 Active, not recruiting Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma
Interventions: Drug: azacitidine;   Drug: lenalidomide
19 Active, not recruiting Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Conditions: T-Cell Peripheral Lymphoma;   Gamma Delta Hepatosplenic T-Cell Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma;   NK T-Cell Lymphoma
Interventions: Drug: Siplizumab (Medi-507);   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Rituximab
20 Completed VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Conditions: B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Lymphoma
Intervention: Drug: VELCADE and rituximab
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years